Marc-Alexander Burmeister – President, B. Braun France
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
For 175 years, B. Braun has been the trusted partner of healthcare facilities through its range of innovative products and services and safety, suitable for all patient treatment steps.
A family group of German origin, B. Braun specializes in the design, production and marketing of medical and surgical equipment, pharmaceutical products and related services. The Group has over 140 subsidiaries worldwide. In 2015, the Group achieved a turnover of over 6.13 billion euros with a workforce of 56,000 employees in 64 countries.
In France, B. Braun develops, manufactures and markets hospital medical devices, implants, and pharmaceutical products in the areas of surgery, infusion, intensive care and regional anesthesia.
B. Braun also accompanied home patients with chronic diseases in the fields of stoma, continence, wound care and diabetes.In 2014, B. Braun achieved a turnover of over EUR 284 million in France .
Contact
B. Braun
204 Avenue du Maréchal
92100 Boulogne
France
+33 1 41 10 53 00
+33 1 41 10 53 99
www.bbraun.fr
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
An early bronchiolitis outbreak has put French paediatric hospital services under pressure and forced the government to react with the provision of EUR 150 million in emergency funds, but this…
French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers. Servier, which is governed…
Exor, led by Fiat brand heirs the Agnelli family, has signed a partnership agreement for an investment of EUR 833 million in the also family-owned French holding, Institut Mérieux, known…
The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies…
France is Europe’s 4th largest pharmaceutical manufacturer, having produced pharmaceuticals valued at €21.9 billion in 2019. In recent years, the French contract development and manufacturing organisation (CDMO) market has seen…
When British executive Paul Hudson joined French pharma Sanofi back in 2019, he was quick to launch a “play to win” strategy, shedding underperforming areas and doubling down on its…
See our Cookie Privacy Policy Here
